drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous HER2 (ERBB2)-targeted CAR T cells engineered with a hypoxia-stimulated CAR expression system to upregulate CAR under low oxygen, enhancing persistence and tumor killing in hypoxic solid tumors.
nci_thesaurus_concept_id
C200187
nci_thesaurus_definition
A preparation of T-lymphocytes that have been genetically modified to express a hypoxia-stimulated chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunostimulating and antineoplastic activities. Upon administration, HER2-targeted hypoxia-stimulated CAR T cells target and bind to HER2-expressing tumor cells, thereby inducing selective toxicity in HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation. Hypoxia-stimulated CAR may improve the expansion and survival of the CAR T cells in the hypoxic tumor microenvironment (TME).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a HER2-specific chimeric antigen receptor whose expression is driven by a hypoxia-inducible system. In hypoxic tumor microenvironments, CAR expression increases, enabling targeted recognition and killing of HER2-positive tumor cells via T-cell activation, cytokine release, and cytotoxicity; hypoxia-regulated expression enhances T-cell persistence/expansion in solid tumors and may reduce off-tumor activity in normoxia.
drug_name
HypoSti.CAR-HER2 T cells
nct_id_drug_ref
NCT05681650